Lymphoma trial tests which chemo combo works best for younger patients
NCT ID NCT00498043
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two different chemotherapy regimens (R-CHOP14 and R-ACVBP14), both combined with the drug rituximab, in 222 adults aged 18 to 59 with an aggressive type of B-cell lymphoma. The goal was to see which combination led to a complete response after four cycles of treatment. The trial also used PET scans to guide further treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab combined with chemotherapy (R-CHOP14 or R-ACVBP14)
What this could lead to
If successful, this could help identify a more effective chemotherapy combination for younger adults with aggressive lymphoma, potentially improving remission rates.
What could go wrong
This is a Phase II trial with only 222 participants, so results may not apply to all patients. The study is completed, but the findings may not lead to a standard treatment change without further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
René Olivier Casasnovas
Dijon, 21000, France